期刊文献+

长春瑞滨联合顺铂治疗非小细胞肺癌的疗效及预后的多因素分析

下载PDF
导出
摘要 目的 探讨接受长春瑞滨联合顺铂治疗非小细胞肺癌病人影响疗效、预后的因素。方法 分别选择临床病理因素,应用Logistic回归及Cox比例风险模型分别对影响疗效、预后的因素进行分析。结果 全组总有效率(RR)为30.2%(62/205),中位生存期8月,1年生存率分别为37.81%、2年生存率15.44%、3年生存率5.39%。多因素分析显示病理类型、治疗前一般状况(PS)与疗效及预后均为影响因素(P<0.05),而性别仅为影响疗效因素(P=0.03),治疗前体重丢失情况(P<0.0005)、完成的治疗的周期数(P<0.0005)为影响预后因素。结论 长春瑞滨联合顺铂是治疗非小细胞肺癌较好的方案,影响疗效重要因素为性别、PS病理类型。完成治疗的总周期致病理类型、PS、治疗前体重丢失情况是影响预后的重要独立指标。
出处 《结核病与胸部肿瘤》 2003年第2期112-118,共7页 Tuberculosis and Thoracic Tumor
  • 相关文献

参考文献9

  • 1Le Chevalier T, Pujol JL, Dorillard JY, et al: Randomized study of vinorelbine and vindesine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced mon-small cell lung cancer J Clin Oncol, 1994; 12:360 - 367.
  • 2S. Julien, P. Jacoulet, A. Dubiez, et 81: Non-Small Cell Lung Cancer: A Study of Long-Term Survival after Vinorebine Monotherapy Reprinted from The Oncologist, 2000; 5:115 - 119.
  • 3Isabelle Monnet, Patrick Soulie, Hubert de Cremoux. et al. Phase Ⅰ /Ⅱ Study of Escalating Dose of Vinorelbine in Combination With Oxaliplation in Patients With Advanced non-small-cell Lung Cancer.J Clin Oncol,2001 ; 19:458 - 463.
  • 4Albain KS, Crowley J J, Leblanc M et al. Survival determinants in extensive-stage non-small-coll lung cancer: the Southwest Oncologe Group Experinece. J Clin Oncol, 1999;9:1618 - 2053.
  • 5Richard G.Sheehan,Edward P et al:The Relative Value of Conventional Staging Procedures for Developing Prognostic Models in Extensive-Stage Small-Cell Lung Cancerj Clin Oncol, 1990; 8:2047 - 2053.
  • 6Kathy S.Albain,JohnJ.Crowley.Michael Le Blanc et al.Survival Determinants in Extensive-Stage Non—Small Cell Lung Can—cer;The Southwest Oncology Group Experience Journal of Clinical Oneology,1991;9:1618—1626.
  • 7Paesmans M,Sculier J P,Libert P et al.European Lung Cancer Working Party:Prognostic factors For survival in advanced onosmall-cell lung cancer:univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1502 patients.J Clin Oneol,1995;13:1221—1230.
  • 8Belani C. P. Interim analysis of a phase listudy of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitace for advanced and metastatic non-small cell lung cancer. Semin. Onco1,2001 ;28 * 4 Suppl. 14) : 14 - 16.
  • 9Weick JK, Crowley J, Natale RB, et al : A randomized trial of five cisplatin containing troatments in patients with metastatic nonsmall cell lung cancer; A southwest Oncology Group study. J Clin Oncol 1992 ;9 : 1157 - 1162.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部